Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, women with severe hair loss after bariatric surgery had lower zinc intake compared to those with mild hair loss, suggesting a possible link between zinc consumption and hair loss severity.

In this multicenter retrospective study, 61.5% of Italian patients with severe alopecia areata achieved significant hair improvement after 52 weeks of treatment with baricitinib, with no major safety issues reported, indicating long-term effectiveness in a real-world setting.

This review discusses the application and potential of baricitinib, a JAK1/2 inhibitor, for treating dermatological diseases like alopecia areata and reports no new clinical results.

This study found that white hair fibers have lower lipid content and different water absorption dynamics compared to brown hair fibers, suggesting differences in their barrier functions.

This study found that while bariatric surgery in Bahrain effectively accelerated weight loss, it was also associated with nutritional deficiencies and gastrointestinal complications.

This study found that loss of epidermal PPARγ in mice altered the expression of many genes related to skin inflammation, keratinization, and sebaceous gland function, indicating its key role in maintaining skin homeostasis.

This review examines the dysregulation of innate immune barriers in the early stages of hidradenitis suppurativa and calls for further research on the role of the hair follicle and immune responses, but reports no new results.

This review discusses the use of baricitinib in dermatology, emphasizing its effectiveness in treating certain dermatoses, while highlighting the need for awareness of its potential side effects and calling for more long-term safety data.

In this study, adolescent patients undergoing laparoscopic bariatric surgery at a specialized center experienced significant reductions in BMI over 36 months, with no major perioperative complications, highlighting the procedure's safety and effectiveness for treating adolescent obesity in experienced settings.

This study found that bariatric surgery led to significant weight loss in patients, but it also resulted in complications like nutrient deficiencies, highlighting the need for dietary compliance and professional follow-up.

This study highlights the recent FDA approval of baricitinib as the first on-label treatment for severe alopecia areata, whereas previous treatments were off-label therapies like systemic steroids and immunosuppressants.

This case report describes a 34-year-old woman who, after Roux-en-Y gastric bypass surgery, experienced improvements in symptoms of dizziness and energy following treatment with oral ferrous sulfate for iron deficiency.

This study reports that baricitinib was more effective than placebo in promoting hair growth in adults with severe alopecia areata after 36 weeks of treatment in clinical trials.

This study found that patients with rheumatoid arthritis, atopic dermatitis, and alopecia areata receiving baricitinib had low incidence rates of adverse events, especially among low-risk individuals, with varying rates among those at higher risk.

This study reports that two phase III trials demonstrated the effectiveness of the oral Janus kinase inhibitor baricitinib at 2 mg or 4 mg daily for treating severe alopecia areata in adults, marking a potential advance in managing this condition.

This study observed that successful weight loss following bariatric surgery may improve some skin conditions and metabolic profiles, but also may lead to a decrease in vitamin B12 levels, suggesting a need for nutritional supplements.

In this study, baricitinib treatment improved the differentiation of skin-derived precursors into adipocytes for diseases like Hutchinson-Gilford progeria syndrome, suggesting potential benefits when combined with lonafarnib.

This study found that baricitinib improved symptoms of atopic dermatitis and alopecia areata in both adults and children in real-world settings, aligning with clinical trial results, while noting low discontinuation due to adverse events and no new safety concerns.

This study suggests that combining baricitinib with narrowband UV-B therapy is an effective and well-tolerated approach for treating active nonsegmental vitiligo.

This study aims to compare the safety and effectiveness of bariatric surgery versus medical care on ovulation rates in women with PCOS and obesity, as current observational data suggests surgery may improve fertility prospects, but no randomized trial has yet confirmed this effect.

This study found that twice-daily oral baricitinib at a 2-mg dose showed promising results in treating refractory alopecia areata, particularly among Chinese patients, with 64% achieving significant hair regrowth, although none attained complete hair regrowth. Adverse events were mild and included nausea and folliculitis.

This study examined phase 3 clinical trial data and found that baricitinib improves hair regrowth in adults with alopecia areata and significant scalp hair loss, with the response varying based on the severity of hair loss at the start of treatment.

Bardet-Biedl syndrome may include under-recognized skin problems related to its metabolic disturbances.

In this case report, a white man with mental retardation and suspected sensory neural hearing loss experienced resolution of cystic lesions and partial regeneration of facial fat after 1.5 months of pimozide therapy.

This study found that calcium microcapsules exhibited better biocompatibility and cell viability than barium microcapsules for scaffolding in artificial dermal papilla, suggesting potential for developing new hair follicle structures.

In this study, researchers developed a dissolvable microneedle patch containing baricitinib for alopecia areata treatment, reporting significantly higher hair growth in mouse models compared to controls, suggesting its potential as an effective, pain-free topical therapy.

Baricitinib is generally safe for long-term use in treating severe alopecia areata.

Baricitinib can lead to hair regrowth in alopecia areata but may also cause relapses.

In this study, baricitinib treatment for severe alopecia areata showed similar safety and led to hair regrowth improvements independent of atopic background, with 40.8% of patients with atopy achieving a significant response compared to 30.2% without atopy when using a 4 mg dose.